Search

Search Constraints

You searched for: Author/Creator Htut, Myo

Search Results

1. A phase 1 dose‐escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Issue 21 (19th July 2016)

3. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Issue 10297 (24th July 2021)

4. Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma. (17th December 2021)

5. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study. Issue 12 (December 2022)

7. Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long‐term follow‐up study. (15th November 2012)

8. Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study. Issue 7 (6th June 2020)

9. Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma. (25th June 2018)